RNAi-tech startup takes lead from psychotropics, medical cannabis veteran with new CEO pick
October 20, 2022 | Startland News Staff
ST. LOUIS — Steve Meyer sees opportunity in RNAissance Ag — an offshoot Kansas City-grown TechAccel — especially its portfolio of safe biopesticides and novel RNAi manufacturing technology.
“I believe the full potential of RNAi-based solutions in agriculture is yet to be seen,” said Meyer, the company’s new CEO. “This innovative technology not only has the potential to offer a much-needed new tool to solve some of the toughest challenges we face in agriculture, but it also promises to revolutionize sustainable agriculture, making it safer for people and our planet.”
Meyer most recently was chief operating officer at Lucy Scientific Discovery Inc., British Columbia, a cGMP manufacturer of psychotropic compounds for therapeutic uses. Before that, he was the co-founder and CEO of Heya Wellness of St. Charles, Missouri, a vertically integrated medical cannabis firm.
RNAissance Ag, which is in the process of expanding its office and lab facilities at Bio Research Development and Growth (BRDG) Park in St. Louis, is a startup founded in 2019 by TechAccel based on a novel RNA-interference (RNAi) technology developed at the Donald Danforth Plant Science Center. RNAi is a technology that regulates gene expression without genetic modification.
Click here to read more about RNAissance Ag.
Kansas City-based TechAccel — a technology and venture development company investing in scientific breakthroughs for healthier plants, animals and foods — opened its facility at BRDG Park in 2021 to give RNAissance Ag and other initiatives room to grow, the company said previously.
Prior to his work with psychotropics and medical cannabis, Meyer worked for 16 years at Monsanto (now Bayer Crop Science) in a variety of scientific and commercial roles. He conducted biotechnology research that led to the development of multiple commercial products and played a key role in transforming the firm’s insect control discovery pipeline, leading to his appointment as a Monsanto Science Fellow.
“Steve has the expertise and leadership to drive the RNAissance Ag technology — both in biomanufacturing and biopesticide development — to commercial success,” said Michael Helmstetter, chairman of the board of directors for RNAissance Ag, as well as founder and president of TechAccel. “Plus, he has an innovator’s mindset and draws upon an extraordinary range of experiences and insights.”
Meyer’s announcement as CEO this week is effective immediately.
The primary focus of RNAissance Ag is the development of sprayable RNAi pesticides against pests such as the Diamondback Moth, Fall Armyworm and several others. RNAissance Ag pesticides are designed to be highly specific to the target pest, are not toxic to other organisms and are biodegradable. RNAissance Ag’s designs also have applications as pesticidal traits in crop seeds.
“I am excited and honored to join RNAissance Ag as its CEO,” Meyer said. “I am very impressed by the quality and caliber of the team, which is at the heart of every great company.”
Featured Business

2022 Startups to Watch
stats here
Related Posts on Startland News
Pioneering KCI airport vote should help land top talent, startup leaders say
Capping a six-year journey fraught with turbulence, delays and political drama, voters overwhelmingly ratified plans to build a new $1.3 billion airport terminal, which would replace the existing Kansas City International Airport (KCI). “Kansas City has never been about being just mediocre,” said Michael Wilson, founder of luxury watch brand Niall and a frequent traveler…
WillCo Tech’s sale allows founder guilt-free $200K investment in smart grid startup
Selling a majority stake in his IT consulting firm will allow Kevin Williams to focus on and expand his startup venture, the Kansas City tech entrepreneur said. Although the exact amount was undisclosed, the acquisition by Ohio-based Metisentry earlier this month provided a big enough payoff to fund Williams’ and his wife’s future retirement, as…
After $2.95M round, corporate deal ensures word-of-mouth marketing for RiskGenius
RiskGenius’ $2.95 million series A extension funding round is worth more than its face value, said CEO Chris Cheatham. The round was led by QBE Ventures, an Australia-based firm known as being among the world’s top 20 insurance companies. In addition to the funds, QBE North America will be the first division to fully implement…
Likarda scaling up biotech research firm with $4M angel boost, new lab
An animal’s diabetes diagnosis comes with a heavy burden for the pet’s owners, Lisa Stehno-Bittel said. And it’s not just the cost of treatment, the president and co-founder of Likarda added. “Of those who will try twice-daily insulin injections, within a year, half of those have given up,” she said. “A lot of that is…


